Home > News > BioSante Pharmaceuticals Reports Product Development Highlights
May 16th, 2005
BioSante Pharmaceuticals Reports Product Development Highlights
Abstract:
BioSante Pharmaceuticals (AMEX:BPA) today reported on certain product development highlights and announced financial results for the first quarter ended March 31, 2005.
"The completion of our pivotal Phase III clinical trial of Bio-E-Gel(TM) and two key announcements highlighting the use of our CaP nanotechnology represent important progress for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer.
Source:
genengnews.com
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||